A Phase IV Observational study to assess Quality of Life in patients with Pancreatic Neuroendocrine Tumors receiving treatment with oral 10 mg Everolimus (Afinitor®) o.d
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms OBLIQUE
- Sponsors Novartis
- 11 Oct 2016 Primary endpoint (EORTC QLQ-C30 score at 6 month of treatment) has not been met,according to the results presented at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 30 Mar 2016 Status changed from active, no longer recruiting to completed.